本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、概况 近日，上海复星医药（集团）股份有限公司（以下简称"本公司"）控股子公 司上海复星医药产业发展有限公司就复迈宁®（通用名：芦沃美替尼片，以下简称"该 药品"）用于治疗儿童低级别脑胶质瘤于中国境内（不包括港澳台地区，下同）启 动Ⅲ期临床试验。 二、该药品的基本信息及研究情况 该药品为本集团（即本公司及控股子公司/单位，下同）自主研发的创新型小分 子化学药物，为 MEK1/2 选择性抑制剂。截至本公告日期（即 2025 年 7 月 9 日）， 该药品的临床或注册情况如下： 证券代码：600196 股票简称：复星医药 编号：临 2025-115 上海复星医药（集团）股份有限公司 关于控股子公司药品临床试验进展的公告 三、风险提示 根据研发经验，药品研发存在一定风险，例如临床试验可能会因为安全性和/ 或有效性等问题而终止。 药品研发及至上市是一项长期工作，存在诸多不确定因素，敬请广大投资者注 意投资风险。 特此公告。 1、该药品已于中国境内上市并获批两项适应症，包括用于治疗（1） ...

复星医药：控股子公司药品芦沃美替尼片中国境内启动Ⅲ期临床试验 智通财经7月9日电，复星医药(600196.SH)公告称，控股子公司上海复星医药产业发展有限公司就复迈 宁®（通用名：芦沃美替尼片）用于治疗儿童低级别脑胶质瘤于中国境内启动Ⅲ期临床试验。该药品为 集团自主研发的创新型小分子化学药物，为MEK1/2选择性抑制剂，已在中国境内上市并获批两项适应 症。截至2025年5月，集团针对该药品的累计研发投入约为人民币6.07亿元。根据IQVIA数据，2024 年，MEK1/2选择性抑制剂于全球范围的销售额约为20.68亿美元。药品研发存在一定风险，敬请广大投 资者注意投资风险。 ...

金融界7月9日消息，A股三大指数收盘涨跌不一，沪深300制药指数(300制药，L11640)报11609.22点。 数据统计显示，沪深300制药指数近一个月下跌2.48%，近三个月上涨5.29%，年至今上涨6.57%。 据了解，沪深300制药指数从沪深300指数中选取与制药主题相对应的行业内上市公司证券作为指数样 本，以反映该主题上市公司证券的整体表现。该指数以2004年12月31日为基日，以1000.0点为基点。 从指数持仓来看，沪深300制药指数十大权重分别为：恒瑞医药（41.61%）、片仔癀（10.46%）、云南 白药（8.71%）、科伦药业（6.52%）、华东医药（6.0%）、新和成（5.88%）、复星医药（5.59%）、 同仁堂（4.26%）、百利天恒（4.09%）、华润三九（3.63%）。 从沪深300制药指数持仓的市场板块来看，上海证券交易所占比69.26%、深圳证券交易所占比30.74%。 从沪深300制药指数持仓样本的行业来看，药品制剂占比63.81%、中成药占比30.31%、原料药占比 5.88%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下 ...

Group 1 - Tong Ren Tang's Executive Vice President Zhang Chunyou submitted a resignation letter, effective July 8, 2025, due to work adjustments, while remaining as General Manager of Tong Ren Tang Technology [1] - The company stated that Zhang Chunyou's departure will not adversely affect daily operations, indicating limited market impact from this internal personnel adjustment [1] Group 2 - Basestone Pharmaceuticals announced an exclusive strategic partnership with Istituto Gentili for the commercialization of Sugliant in Western Europe and the UK, granting Gentili exclusive rights in 23 countries [2] - Basestone will receive up to $192.5 million in payments, including upfront, registration, and sales milestone payments, along with nearly 50% revenue sharing from net sales in the authorized region [2] - This collaboration enhances Basestone's international market recognition and strengthens investor confidence in future growth [2] Group 3 - Fosun Pharma announced guarantees for its subsidiaries, providing a maximum joint liability guarantee for a financing application not exceeding 500 million yuan with Bank of China [3] - Additionally, a guarantee was provided for a financing contract not exceeding 150 million yuan with China Construction Bank for its subsidiary Hanlin Pharmaceutical [3] - This move supports subsidiaries in obtaining funds for business expansion or R&D, although it introduces certain financial risks [3] Group 4 - Run Da Medical responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, addressing issues related to operating performance, goodwill, short-term solvency, and prepayments [4] - The response aims to alleviate market concerns and stabilize investor confidence, although ongoing monitoring of the company's performance improvement measures is necessary [4] Group 5 - Yuan Da Pharmaceutical announced that its joint venture Sirtex Medical Pty Ltd received FDA approval for SIR-Spheres Yttrium-90 microspheres for treating unresectable hepatocellular carcinoma (HCC) [5] - This product is the first and only FDA-approved selective internal radiation therapy for both unresectable HCC and colorectal cancer liver metastases [5] - This breakthrough enhances Yuan Da's market position in oncology and boosts investor confidence in future growth [5]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 董事長 陳玉卿 中國，上海 2025 年7 月8 日 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 為控股子公司提供擔保的進展公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 歸還用於暫時補充流動資金的募集資金的公告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 董事長 上海复星医药（集团）股份有限公司 关于归还用于暂时补充流动资金的募集资金的公告 陳玉卿 中國，上海 2025 年7 月8 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全 ...

证券代码：600196 证券简称：复星医药 公告编号：临 2025-114 上海复星医药（集团）股份有限公司 关于为控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 担保对象及基本情况 | | 名称 | 复星医药产业 | | --- | --- | --- | | 被担保方 1 | 本次担保金额 截至 2025 年 7 月 7 日，包 | 人民币 50,000 万元 | | | 括本次担保在内，本集团 实际为其提供的担保余额 | 折合人民币约 964,103 万元 | | | 是否在前期预计额度内 | 是 □否 □不适用：_________ | | | 本次担保是否有反担保 | 被担保方 1 系担保方 1 之全资子公司， 不涉及反担保安排 | | 被担保方 2 | 名称 | 汉霖制药 | | | 本次担保金额 | 人民币 15,000 万元 | | | 截至 2025 年 7 月 7 日，包 括本次担保在内，本集团 实际为其提供的担保余额 | 人民币 126,550 万元 | | | 是否在前期预 ...

经 2024 年 7 月 9 日召开的上海复星医药（集团）股份有限公司（以下简称"本 公司"）第九届董事会第五十四次会议及第九届监事会 2024 年第六次会议审议通过， 同意本公司 2022 年非公开发行 A 股（以下简称"本次发行"）的募投项目实施主体 （包括本公司及负责本次发行募投项目实施的控股子公司，以下合称"募投实施主 体"）使用合计不超过人民币 41,000 万元的闲置募集资金暂时补充流动资金，使用 期限自董事会审议通过该事项之日（即 2024 年 7 月 9 日）起不超过 12 个月（以下 简称"暂时补流授权"）。 截至 2025 年 7 月 7 日，相关募投实施主体已将上述暂时补流授权项下用于暂时 补充流动资金的款项全部归还至相应的募集资金专项账户。本公司亦已将上述归还 情况通知本次发行的保荐机构中国国际金融股份有限公司及其保荐代表人。 特此公告。 上海复星医药（集团）股份有限公司 董事会 证券代码：600196 股票简称：复星医药 编号：临 2025-113 上海复星医药（集团）股份有限公司 关于归还用于暂时补充流动资金的募集资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 ...

Core Viewpoint - Fosun Pharma's self-developed drug, Luwo Meitini tablets, has been officially launched for clinical use, marking it as China's first and only targeted drug approved for both adult Langerhans cell histiocytosis (LCH) and neurofibromatosis type 1 (NF1) in children aged 2 and above, providing new treatment options for rare disease patients [1][2]. Group 1: Drug Approval and Clinical Use - Luwo Meitini tablets received approval from the National Medical Products Administration (NMPA) on May 29 and were put into clinical use in Beijing and other cities within a month, addressing the dual challenges of "no available drugs" and "difficult access to drugs" for rare disease patients [1]. - The drug is expected to significantly improve drug accessibility for patients suffering from rare diseases, filling a treatment gap in the domestic market [1]. Group 2: Impact on NF1 Patients - NF1 is a rare genetic disorder that can severely impact patients' quality of life, with surgical interventions often limited in effectiveness [2]. - Luwo Meitini tablets are the first targeted drug approved for NF1 in China, showing promising clinical data with good efficacy and controllable safety, offering new hope for patients who cannot undergo surgery or have unsatisfactory surgical outcomes [2][3]. Group 3: Clinical Data and Efficacy - Luwo Meitini is a novel small molecule targeted drug that inhibits MEK1/2 protein activity, blocking the abnormal activation of the MAPK signaling pathway, thus suppressing tumor cell proliferation and inducing apoptosis [3]. - Phase II clinical trials showed a median follow-up of 15.1 months, with an objective response rate (ORR) of 60.5% and a median time to response (TTR) of 4.7 months, indicating rapid efficacy and good tolerability [3]. Group 4: Broader Implications for Rare Tumors - The drug also addresses a significant unmet need in the treatment of adult LCH and other histiocytic tumors, with an ORR of 82.8% in a Phase II trial for 29 patients, and a median time to response of only 2.9 months [4]. - Future clinical trials are planned for additional conditions, including low-grade gliomas and pediatric LCH, indicating the potential for broader applications of Luwo Meitini [4].

Core Insights - The Chinese health technology market is attracting multinational giants due to its large scale and promising prospects, with Intuitive Surgical actively expanding its presence through a "local manufacturing + talent cultivation" dual-driven model [1][2] Company Overview - Intuitive Surgical established a joint venture with Fosun Pharma in 2017, named Intuitive Fosun, to penetrate the Chinese market [1] - The Intuitive Fosun Innovation Center, inaugurated in 2021 in Shanghai, is the first international standard surgical robot training base in China, enabling local doctors to receive training without going abroad [1] - The new headquarters in Shanghai, set to open in June 2024, will have an investment exceeding 700 million yuan and cover an area of over 45,000 square meters, serving as the largest integrated R&D, production, and training base for Intuitive Surgical in the Asia-Pacific region [1] Talent Development - The training capabilities of the Intuitive Fosun Innovation Center have been upgraded, with the Da Vinci training curriculum receiving accreditation from the Royal College of Surgeons (RCS) in 2022, making it the first surgical robot company in China to offer such internationally recognized courses [2] - The center has developed an immersive teaching system covering various surgical specialties, providing personalized courses from basic operations to complex surgeries, enhancing the professional skills of over 6,300 surgical healthcare professionals [2] - Intuitive Fosun collaborates with over 20 top-tier hospitals to establish "Da Vinci Surgical Robot Training Teaching Centers," creating a "medical-education integration" training system [2] Strategic Vision - The CEO of Intuitive Fosun, Dr. Liu Fu-jun, emphasized the importance of a collaborative innovation model involving hospitals, enterprises, and regulators to create a complete feedback loop from technical training to professional education and clinical application [2] - The company is entering a new phase of "local manufacturing" and "talent cultivation," aiming to accelerate the clinical transformation of cutting-edge technologies to benefit more local patients [2]